checkAd
    NewAmsterdam Pharma Company Aktie
    17,300
     
    EUR
    +1,17 %
    +0,200 EUR
    Letzter Kurs 31.05.24 Tradegate
    17,200
     
    EUR
    233 STK
    Geldkurs 31.05.24
    17,400
     
    EUR
    228 STK
    Briefkurs 31.05.24
    ISIN: NL00150012L7 · WKN: A3DUAC · SYM: KH6 · Niederlande

    Neueste Nachrichten

    NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
    29.05.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
    21.05.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
    09.05.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    03.05.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
    02.05.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
    09.04.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
    01.04.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
    25.03.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
    12.03.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
    28.02.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
    26.02.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
    14.02.24 · globenewswire · NewAmsterdam Pharma Company